NO944443D0 - Monoklonale antistoffer - Google Patents

Monoklonale antistoffer

Info

Publication number
NO944443D0
NO944443D0 NO944443A NO944443A NO944443D0 NO 944443 D0 NO944443 D0 NO 944443D0 NO 944443 A NO944443 A NO 944443A NO 944443 A NO944443 A NO 944443A NO 944443 D0 NO944443 D0 NO 944443D0
Authority
NO
Norway
Prior art keywords
monoclonal antibodies
monoclonal
cancer
antibodies
prophylactic
Prior art date
Application number
NO944443A
Other languages
English (en)
Other versions
NO316120B1 (no
NO944443L (no
Inventor
Helmut Eckert
Herbert Jaksche
Evelyne Janzek
Hans Loibner
Dieter Scholz
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929210929A external-priority patent/GB9210929D0/en
Priority claimed from GB929210944A external-priority patent/GB9210944D0/en
Priority claimed from GB929210930A external-priority patent/GB9210930D0/en
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of NO944443D0 publication Critical patent/NO944443D0/no
Publication of NO944443L publication Critical patent/NO944443L/no
Publication of NO316120B1 publication Critical patent/NO316120B1/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • AIDS & HIV (AREA)
NO19944443A 1992-05-22 1994-11-21 Monoklonale anti-idiotypiske antistoffer, fremgangsmåte for fremstilling ogfarmasöytiske preparater av disse, samt anvendelse NO316120B1 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB929210929A GB9210929D0 (en) 1992-05-22 1992-05-22 Monoclonal antibodies and their use
GB929210944A GB9210944D0 (en) 1992-05-22 1992-05-22 Monoclonal antibodies and their use
GB929210930A GB9210930D0 (en) 1992-05-22 1992-05-22 Monoclonal antibodies and their use
PCT/EP1993/001215 WO1993024647A1 (en) 1992-05-22 1993-05-14 Anti-idiotypic monoclonal antibodies against the lewis y-specific monoclonal antibody br55-2 and their uses

Publications (3)

Publication Number Publication Date
NO944443D0 true NO944443D0 (no) 1994-11-21
NO944443L NO944443L (no) 1995-01-20
NO316120B1 NO316120B1 (no) 2003-12-15

Family

ID=27266199

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19944443A NO316120B1 (no) 1992-05-22 1994-11-21 Monoklonale anti-idiotypiske antistoffer, fremgangsmåte for fremstilling ogfarmasöytiske preparater av disse, samt anvendelse

Country Status (20)

Country Link
EP (1) EP0644947B1 (no)
JP (3) JPH07507207A (no)
KR (1) KR100279317B1 (no)
AT (1) ATE179214T1 (no)
AU (1) AU678160B2 (no)
CA (1) CA2134751C (no)
CZ (1) CZ286547B6 (no)
DE (1) DE69324584T2 (no)
DK (1) DK0644947T3 (no)
ES (1) ES2133395T3 (no)
FI (1) FI111518B (no)
GR (1) GR3030701T3 (no)
HU (1) HU219055B (no)
NO (1) NO316120B1 (no)
NZ (1) NZ252161A (no)
PL (1) PL175651B1 (no)
RU (1) RU2208642C2 (no)
SG (1) SG50721A1 (no)
SK (1) SK281086B6 (no)
WO (1) WO1993024647A1 (no)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT500650B1 (de) * 2003-04-17 2009-11-15 Altropus Gmbh Immunogener rekombinanter antikörper
BRPI0413575A (pt) * 2003-08-14 2006-10-17 Wyeth Corp anticorpos anti-idiotìpicos anti-lewis y e seus usos
AT504231A1 (de) 2006-10-03 2008-04-15 Hans Dr Loibner Prädiktive parameter
US10150817B2 (en) 2010-09-01 2018-12-11 Biogen Ma Inc. Rapid generation of anti-idiotypic antibodies
RU2735653C2 (ru) * 2016-08-23 2020-11-05 Тран-Сцелл Биологицс Привате Лимитед Платформа с клетками-предшественниками человека для поиска активных веществ лекарственных препаратов

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68926454T2 (de) * 1988-07-06 1997-01-09 Verigen Inc N D Ges Des Staate Gegen hiv 1 gp48 spezifische antikörper
DE4006308A1 (de) * 1990-02-28 1991-08-29 Sandoz Ag Verwendung des monoklonalen antikoerpers br 55.2 gegen kleinzelliges lungenkarzinom
DE4025499A1 (de) * 1990-08-11 1992-02-13 Sandoz Ag Verwendung der antikoerper br55-2, deren derivate, konjugate und fragmente zur bekaempfung von hiv-infektionen
ES2145004T3 (es) * 1991-08-21 2000-07-01 Novartis Ag Derivados de anticuerpos.

Also Published As

Publication number Publication date
NZ252161A (en) 1996-10-28
JPH07507207A (ja) 1995-08-10
JPH11178594A (ja) 1999-07-06
DE69324584D1 (de) 1999-05-27
HU219055B (hu) 2001-02-28
FI111518B (fi) 2003-08-15
NO316120B1 (no) 2003-12-15
SK281086B6 (sk) 2000-11-07
SK139894A3 (en) 1995-07-11
FI945485A (fi) 1994-11-22
CA2134751C (en) 2003-12-16
ATE179214T1 (de) 1999-05-15
JP2006143738A (ja) 2006-06-08
GR3030701T3 (en) 1999-11-30
KR950701685A (ko) 1995-04-28
WO1993024647A1 (en) 1993-12-09
NO944443L (no) 1995-01-20
DK0644947T3 (da) 1999-11-01
FI945485A0 (fi) 1994-11-22
DE69324584T2 (de) 1999-09-23
CZ286547B6 (cs) 2000-05-17
ES2133395T3 (es) 1999-09-16
AU678160B2 (en) 1997-05-22
CA2134751A1 (en) 1993-12-09
SG50721A1 (en) 2000-11-21
EP0644947B1 (en) 1999-04-21
RU94046321A (ru) 1997-01-27
PL175651B1 (pl) 1999-01-29
KR100279317B1 (ko) 2001-01-15
EP0644947A1 (en) 1995-03-29
AU4068893A (en) 1993-12-30
RU2208642C2 (ru) 2003-07-20
HUT71311A (en) 1995-11-28
CZ285194A3 (en) 1995-05-17

Similar Documents

Publication Publication Date Title
NZ568769A (en) Human monoclonal antibodies against CD20
DK0528767T3 (da) antistofderivater
NO175944C (no) Monoklonale antistoffer for anvendelse til in vitro påvisning av tumorassosiert mucinantigen, og hybridomcellelinjer som produserer disse
FI840219A0 (fi) Human-humanhybridom foer neoplasmer
NO994983D0 (no) Fremgangsmåte for fremstilling av anti-humane antigenreseptorer, samt anvendelse av disse
ATE171207T1 (de) Monoklonaler antikörper
OA08485A (fr) Monoclonal antibodies and antigen for human non-small cell lung carcinoma and certain other human carcinomas.
ATE115412T1 (de) Anti-idiotyp-antikörper gegen antimenschliche hochmolekulare, an melanomen assoziierte antigene.
NO944443D0 (no) Monoklonale antistoffer
PT840620E (pt) Antagonistas de il-8 para o tratamento de asma
NO922941D0 (no) Medikamenter og fremgangsmaater for behandling av aids og aids-relatert kompleks ved anvendelse av anti-karbohydrat-antistoffer og karbohydrat-antigener
DE69118702D1 (de) Neue verwendung eines monoklonalen antikörpers
ZA912695B (en) Monoclonal anti-igm antibodies,their production and use,and hybridomas for producing the same
ATE263784T1 (de) Anti-megakaryozyten monoklonaler antikörper 97a6
ATE169332T1 (de) Monoklonaler antikörper gegen den extravillösen trophoblast
SE8401946D0 (sv) Antibody to human prostate cancer
ATE343596T1 (de) Humane monoklonale antikörper gegen inselzellantigen ia-2
SE9404491D0 (sv) Process for the production of human monoclonal antibodies
AU6162794A (en) Carcinoma associated antigen (ng1) monoclonal antibodies against ng1, methods of producing these antibodies and use therefor
NO874798D0 (no) Fremgangsmaate for fremstilling av monoklonale antistoffer ved dyrking av hybridom-cellelinjen lym-1.
BG50103A1 (en) Hybridome cell line, secretting monoclonal antibody against antigene determinante noc- 2 of malignant melanom in human
NO874799D0 (no) Fremgangsmaate for fremstilling av monoklonale antistoffer ved dyrking av hybridom-cellelinjen lym-2.